Peptides DB
Research-centric peptide and protocol reference hub
Study 86 of 88HGH (Somatropin) literatureGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · Observational2026

An assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.

Generic PROMs are more likely to be usable and accessible for assessing quality of life in children receiving rhGH therapy, while cost and unclear fee structures pose significant barriers for condition-specific measures.

Read at Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research SocietyAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
4
Preclinical
59
Observational · this one
1
Open-label
15
Randomised
9
Reviews

Summary and findings

This study evaluated the usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy. A total of 50 patient-reported outcome measures (PROMs) were identified, with 37 remaining after exclusions. Key findings included that 16 (43%) were available in self-report and parent-proxy formats in over 30 languages.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
24 (65%) had a reported completion time less than 15 min.2026

Abstract

The authors’ words, as Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society supplied them

<h4>Background</h4>In the field of childhood growth hormone therapy (rhGH), patient and parent/observer-reported outcome measures (PROMs) are rarely used routinely.<h4>Aim</h4>To identify barriers and facilitators for the global implementation of PROMs for evaluating QoL in children receiving rhGH.<h4>Methods</h4>PROMs used in childhood rhGH therapy that were identified through a narrative literature search and expert group consultation were evaluated on reporter's perspective, language availability, administration mode, cost, age range, and completion time.<h4>Results</h4>Of the 50 PROMs identified, 13 were excluded due to methodological limitations. Of the remaining 37, that included 26 generic and 11 condition-specific PROMs, 16 (43%) were available in self-report and parent-proxy formats in over 30 languages and 24 (65%) had a reported completion time less than 15 min. The median lower age limit was 7 yrs (range: 3.0, 12.7). Of the 37, 7 (19%) were free to use, 12 (32%) required a fee, and for 18 (49%), the cost was unclear or varied between clinical practice and research. The mostly commonly represented domains in the condition-specific PROMs included "physical functioning & symptoms" and "emotional & mental health". Fees for condition-specific PROMs were often not explicit, and none were unconditionally free of charge. Overall, generic PROMS tended to rank higher across the six usability parameters than condition-specific tools.<h4>Conclusion</h4>Cost and unclear fee structures represent barriers to the routine use of condition-specific PROMs for assessing rhGH therapy in real-world settings. Whilst both, generic and condition-specific PROMs play important complementary roles, the former are more likely to exhibit characteristics that support global implementation.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the HGH (Somatropin) corpus

BDose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · n=118 · ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.HumanAOnce-weekly somatrogon versus daily somatropin in pediatric growth hormone deficiency: A systematic review and meta-analysis.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewCDeciphering the In Vivo Fate of PEGylated rhGH via a Molecular Ruler-Based MS Strategy.Analytical chemistry · plasma half-life t1/2 = 26.83 hAnimalBLong-acting growth hormone therapy in Chinese children with idiopathic short stature: efficacy evaluation and influencing factors.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · n=180 · -1.47 ± 0.31 HtSDS vs -1.63 ± 0.48 in control, p<0.001 after 12 monthsHumanDGH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · Complete GHD showed greater first-year height velocity (HV) than ISS (MD +0.80 cm/year; 95% CI 0.52-1.08).reviewBInfluence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study.Journal of endocrinological investigation · 2026 · IGF-I SDS increased significantly in both groups (p<0.001).Human